Organization
South San Francisco, CA
11 abstracts
Abstract
Practice- and provider-level inequities in next-generation sequencing (NGS) testing by race/ethnicity for patients (pts) with advanced non-small cell lung cancer (aNSCLC) treated in the community setting.Org: The West Cancer Center, OneOncology, Foundation Medicine, Inc., Cambridge, MA, Genentech Inc., Flatiron Health, San Francisco, CA,
Abstract
Circulating kidney injury molecule-1 (KIM-1) biomarker analysis in IMmotion010: A randomized phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with renal cell carcinoma (RCC) at increased risk of recurrence after resection.Org: Gustave Roussy Cancer Center, Université Paris Saclay, Paris, France, Royal Free London NHS Foundation Trust, UCL Division of Surgery and Interventional Science,
Abstract
Data-driven strategies for enhancing diversity in oncology clinical trials: Optimization of eligibility criteria.Org: Flatiron Foundation Medicine Insights Lab, New York, NY, Emory University, Atlanta, GA, USA, Atlanta, GA, Genentech Inc.,
Abstract
Demographics of cancer screening in Providence’s homeless population.Org: Rhode Island Hospital, Legorreta Cancer Center, Brown University School of Medicine-Rhode Island Hospital, Providence, RI, Brown Physicians Inc,
Abstract
Information and support needs of young Black women with early breast cancer to enable self-management and informed decisions during breast cancer treatment.Org: Center for Business Models in Healthcare, Glencoe, IL, Glencoe, IL, Tigerlily Foundation, Stone Ridge, VA, Genentech Inc.,
Abstract
Real-world cost of disease progression (PD) after frontline (1L) R-CHOP in diffuse large B-cell lymphoma (DLBCL): An analysis of a large US claims database.Org: Rocky Mountain Cancer Centers, The US Oncology Network, Aurora, CO, Genentech, South San Francisco, CA,
Abstract
Patients’ voices matter: Translating pretreatment patient-reported outcomes into high and low health-related quality of life provides a new clinical aspect on prognosis and survival in patients with previously untreated diffuse large B‐cell lymphoma.Org: F. Hoffmann-La Roche Ltd, Mississauga, ON, Canada, Genentech Inc., South San Francisco, CA, Genentech,
Abstract
AFT-50 EndoMAP: A phase IB/II multi-cohort study of targeted agents for patients with recurrent or persistent endometrial cancer.Org: Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, University of Chicago, Chicago, IL,
Abstract
Concordance among the three commercially available PD-L1 assays for esophageal squamous cell carcinoma.Org: Roche (China) Holding Ltd., Shanghai, China, Gracell Biotechnologies, Ltd., National Taiwan University Cancer Center/Hospital, Taipei, Taiwan, National Taiwan University Biomedical Park Hospital,
Abstract
Phase 1b clinical study of IRAK 1/4 inhibition for low-risk myelodysplastic syndromes refractory/resistant to prior therapies.Org: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Houston, TX, Rigel Pharmaceuticals, Inc., South San Francisco, CA,
Abstract
Olutasidenib in post-venetoclax patients with mIDH1 AML.Org: Georgia Cancer Center, Augusta University, Medical College of Georgia at Augusta University, Augusta, GA, Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine at UCLA,